Atnaujinkite slapukų nuostatas

El. knyga: Anticancer Therapeutics: From Drug Discovery to Clinical Applications

(University of Sydney), (Newcastle University), (Newcastle University)
  • Formatas: EPUB+DRM
  • Išleidimo metai: 11-Dec-2017
  • Leidėjas: John Wiley & Sons Inc
  • Kalba: eng
  • ISBN-13: 9781118696200
Kitos knygos pagal šią temą:
  • Formatas: EPUB+DRM
  • Išleidimo metai: 11-Dec-2017
  • Leidėjas: John Wiley & Sons Inc
  • Kalba: eng
  • ISBN-13: 9781118696200
Kitos knygos pagal šią temą:

DRM apribojimai

  • Kopijuoti:

    neleidžiama

  • Spausdinti:

    neleidžiama

  • El. knygos naudojimas:

    Skaitmeninių teisių valdymas (DRM)
    Leidykla pateikė šią knygą šifruota forma, o tai reiškia, kad norint ją atrakinti ir perskaityti reikia įdiegti nemokamą programinę įrangą. Norint skaityti šią el. knygą, turite susikurti Adobe ID . Daugiau informacijos  čia. El. knygą galima atsisiųsti į 6 įrenginius (vienas vartotojas su tuo pačiu Adobe ID).

    Reikalinga programinė įranga
    Norint skaityti šią el. knygą mobiliajame įrenginyje (telefone ar planšetiniame kompiuteryje), turite įdiegti šią nemokamą programėlę: PocketBook Reader (iOS / Android)

    Norint skaityti šią el. knygą asmeniniame arba „Mac“ kompiuteryje, Jums reikalinga  Adobe Digital Editions “ (tai nemokama programa, specialiai sukurta el. knygoms. Tai nėra tas pats, kas „Adobe Reader“, kurią tikriausiai jau turite savo kompiuteryje.)

    Negalite skaityti šios el. knygos naudodami „Amazon Kindle“.

An integrated presentation of the basic science and clinical applications of anticancer agents

Aimed at both undergraduate and postgraduate readers, this unique text provides readers with a fully-integrated presentation of all aspects of the science of anticancer drugs, including their chemistry, pharmacology, and clinical applications.

After heart disease, cancer is the number one killer worldwide, and the tumor microenvironment is forever changing, creating an ever-greater demand for safer, more effective anticancer agents. In response to that demand, the $100 billion cancer drug market continues to grow, with our increased understanding of cancer leading to new drugs being used clinically almost every year.

Anticancer Therapeutics is divided into three sections. Section 1 is an introduction to cancer and therapeutics, and covers the etiology and cellular and molecular basis of cancer. In Section 2, the authors focus on the anticancer agents — their discovery, synthesis, mode of action, mechanisms of resistance, and adverse reactions. Section 3 focuses on specific cancers, explaining how and why the various agents discussed in Section 2 are used, both individually and in combination, to treat different cancers.

  • Integrates aspects of basic science, including chemistry and pharmacology and clinical medicine in relation to cancer therapeutics
  • Written by an author team comprising specialists in medicinal chemistry, pharmacology, and oncology
  • Features full-color images throughout illustrating how drugs bind to cellular targets and exert their pharmacological effect
  • Divided into three sections, covering the etiology and cellular and molecular basis of cancer, anticancer agents, and drug applications for different cancers.

Providing the reader with an integrated understanding of all aspects of the science of anticancer agents, this is an ideal textbook for undergraduates studying medicine, nursing, medicinal chemistry, pharmacy, pharmacology and other allied heath / life sciences. It is also a valuable bench reference for pharmacists, medics, and pharmaceutical researchers working in both academia and industry.

Preface xi
Section 1 Introduction
1(80)
1.1 The Global Burden of Cancer
3(10)
References
11(2)
1.2 Cancer Staging and Classification
13(26)
1.2.1 Benign Tumour (or neoplasm)
13(1)
1.2.2 Malignant Tumour (or cancer)
14(1)
1.2.3 Tumour Nomenclature and Classification
14(7)
1.2.4 Cellular Differentiation and Tumour Grade
21(3)
1.2.5 Tumour Invasion and Metastasis
24(2)
1.2.6 Clinical Staging of Cancer
26(10)
References
36(3)
1.3 Cellular and Molecular Basis of Cancer
39(42)
1.3.1 Oncogenes
40(5)
1.3.2 Tumour Suppressor Genes
45(4)
1.3.3 Role of Epigenetics and Gene Promoter Regulation in Tumourigenesis
49(4)
1.3.4 Multistage Tumourigenesis
53(1)
1.3.5 Oncogene Addiction
54(1)
1.3.6 Hallmarks of Cancer
55(18)
1.3.7 Principles of Cancer Treatment
73(4)
References
77(4)
Section 2 The Anticancer Agents
81(194)
2.1 Agents Which Act Directly on DNA
83(98)
2.1.1 Nitrogen Mustards and Nitrosoureas
83(13)
References
96(2)
2.1.2 Temozolomide
98(8)
References
106(2)
2.1.3 Platinum-containing Agents
108(10)
References
118(2)
2.1.4 Gemcitabine
120(8)
References
128(1)
2.1.5 Camptothecin and Its Analogues
128(11)
References
139(2)
2.1.6 Podophyllotoxins
141(9)
References
150(1)
2.1.7 Anthracyclines
151(9)
References
160(2)
2.1.8 Epigenetic Targeting Agents
162(15)
References
177(4)
2.2 Antimetabolites
181(30)
2.2.1 Cytarabine
181(2)
References
183(1)
2.2.2 Methotrexate
184(11)
References
195(1)
2.2.3 5-Fluorouracil
196(9)
References
205(1)
2.2.4 6-Mercaptopurine
206(4)
References
210(1)
2.3 Antimicrotubule Agents
211(22)
2.3.1 Taxanes
211(13)
References
224(1)
2.3.2 Vinca Alkaloids
225(6)
References
231(2)
2.4 Anti-hormonal Agents
233(24)
2.4.1 Bicalutamide
233(6)
References
239(1)
2.4.2 Tamoxifen
240(7)
References
247(1)
2.4.3 Anastrozole
248(6)
References
254(3)
2.5 Kinase Inhibitors
257(18)
2.5.1 Discovery
257(5)
2.5.2 Synthesis
262(5)
2.5.3 Mode of Action
267(1)
2.5.4 Mechanism of Resistance
268(1)
2.5.5 Adverse Drug Reactions
268(3)
References
271(4)
Section 3 The Cancers
275(142)
3.1 Breast Cancer
277(16)
Key points
277(1)
3.1.1 Epidemiology
277(2)
3.1.2 Presentation
279(3)
3.1.3 Diagnosis
282(1)
3.1.4 Staging
283(2)
3.1.5 Treatments
285(4)
References
289(4)
3.2 Colorectal Cancer
293(14)
Key points
293(1)
3.2.1 Epidemiology
293(1)
3.2.2 Presentation
294(2)
3.2.3 Diagnosis
296(2)
3.2.4 Staging
298(1)
3.2.5 Treatments
299(4)
References
303(4)
3.3 Leukaemia
307(16)
Key points
307(1)
3.3.1 Epidemiology
307(3)
3.3.2 Presentation
310(1)
3.3.3 Diagnosis
311(2)
3.3.4 Staging
313(1)
3.3.5 Treatments
314(5)
References
319(4)
3.4 Lung Cancer
323(16)
Key points
323(1)
3.4.1 Epidemiology
323(4)
3.4.2 Presentation
327(1)
3.4.3 Diagnosis
327(3)
3.4.4 Staging
330(1)
3.4.5 Treatments
330(7)
References
337(2)
3.5 Oesophageal Cancer
339(14)
Key points
339(1)
3.5.1 Epidemiology
339(1)
3.5.2 Presentation
340(1)
3.5.3 Diagnosis
341(3)
3.5.4 Staging
344(2)
3.5.5 Treatments
346(4)
References
350(3)
3.6 Ovarian Cancer
353(14)
Key points
353(1)
3.6.1 Epidemiology
353(1)
3.6.2 Presentation
354(2)
3.6.3 Diagnosis
356(1)
3.6.4 Staging
357(1)
3.6.5 Treatments
357(6)
References
363(4)
3.7 Pancreatic Cancer
367(12)
Key points
367(1)
3.7.1 Epidemiology
367(1)
3.7.2 Presentation
368(2)
3.7.3 Diagnosis
370(1)
3.7.4 Staging
371(2)
3.7.5 Treatments
373(2)
References
375(4)
3.8 Prostate Cancer
379(14)
Key points
379(1)
3.8.1 Epidemiology
379(2)
3.8.2 Presentation
381(1)
3.8.3 Diagnosis
382(2)
3.8.4 Staging
384(3)
3.8.5 Treatments
387(4)
References
391(2)
3.9 Skin Cancers
393(12)
Key points
393(1)
3.9.1 Epidemiology
393(1)
3.9.2 Presentation
394(1)
3.9.3 Diagnosis
395(1)
3.9.4 Staging
396(3)
3.9.5 Treatments
399(4)
References
403(2)
3.10 Testicular Cancer
405(12)
Key points
405(1)
3.10.1 Epidemiology
405(2)
3.10.2 Presentation
407(1)
3.10.3 Diagnosis
407(2)
3.10.4 Staging
409(1)
3.10.5 Treatments
409(5)
References
414(3)
Index 417
Adam Todd, PhD is Senior Lecturer in Pharmaceutical Public Health in the School of Pharmacy, Faculty of Medical Sciences, at Newcastle University, UK. He is registered pharmacist, and specializes in oncology and palliative care.

Paul W. Groundwater, PhD is Professor of Medicinal Chemistry in the Faculty of Pharmacy at The University of Sydney, Sydney, Australia.

Jason H. Gill, PhD is a Reader in Molecular Therapeutics in the School of Pharmacy, Faculty of Medical Sciences, at Newcastle University, UK.